| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | August 12, 2021 3:00 P.M. |
| Form: | F-4 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | August 12, 2021 3:00 P.M. |
| Form: | F-4 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
6-K - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)
6-K - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)
6-K - Quoin Pharmaceuticals, Ltd. (0001671502) (Filer)
Tel Aviv , Oct. 15, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP") (the "Company"), announced today the record date and distribution date for the contingent value rights (the "CVRs") to be distributed in connection with the previously announced strategic merger with privately-held Quoin Pharmaceuticals, Inc., a specialty pharmaceutical company focused on rare and orphan diseases (the "Merger") and the sale of the Company's subsidiary, Cellect Biotherapeutics Ltd., to EnCellX, Inc., a privately held company based in San Diego, CA (the "Share Transfer"). Upon the closings of the Merger and Share Transfer, the Depositary for the Company's American Depositary Shar
Tel Aviv, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), announced shareholders voted to approve the previously announced strategic merger agreement with privately-held Quoin Pharmaceuticals, a specialty pharmaceutical company focused on rare and orphan diseases, and all other proposals presented at the Special General Meeting of shareholders held on September 26, 2021, including the sale of the Company's subsidiary, Cellect Biotherapeutics Ltd, to EnCellX Inc. , a privately held company based in San Diego, CA. Approximately 99% of the votes cast on the strategic merger agreement at the Special General Meeting voted in favor of approving the proposal. The
Tel Aviv, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Reflecting continued clinical progress, Cellect Biotechnology Ltd. (NASDAQ: "APOP"), announced the first ApoGraftTM transplantation in a Leukemia patient in the Company's clinical trial at Washington University in the U.S. ApoGraftTM is a product based on the Company's cell selection technology designed to optimize immune therapy, in this application - prevent graft-versus-host disease (GVHD) following bone marrow transplantation. Following the closing of the previously announced strategic merger transaction between Cellect and Quoin Pharmaceuticals, ApoGraftTM development will be pursued by EnCellX, the privately held U.S. based company that
SC 13G - Quoin Pharmaceuticals, Ltd. (0001671502) (Subject)
SC 13G/A - Cellect Biotechnology Ltd. (0001671502) (Subject)